Linked Life Data

10496201

Source:http://linkedlifedata.com/resource/pubmed/id/10496201

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1999-11-2
pubmed:abstractText
BACKGROUND: Chronic heart failure (CHF) is an increasing burden to health care. Pharmacological treatment with angiotensin-converting enzyme (ACE) inhibitors and beta blockers improve survival and reduce hospitalizations in patients with low left ventricular ejection fraction (LVEF). Despite these therapies, morbidity and mortality remains problematic. Furthermore, 30% to 50% of patients with CHF have a preserved LVEF. It is not known if treatments are of benefit in this group. DESIGN: Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity (CHARM) is a program designed to investigate the clinical usefulness of the long-acting angiotensin II type 1 receptor blocker, candesartan cilexetil, in a broad spectrum of patients with symptomatic heart failure. Patients with systolic dysfunction, tolerant or intolerant to an ACE-inhibitor, and patients with preserved systolic function are included. Specifically, the CHARM program consists of 3 independent, parallel, placebo-controlled studies in patients with (1) LVEF less than or equal to 40%, ACE-inhibitor treated (n = 2,300); (2) LVEF less than or equal to 40%, ACE-inhibitor intolerant (n = 1,700); (3) LVEF greater than 40%, not treated with ACE inhibitors (n = 2,500). The 3 studies will be combined to evaluate the effect of candesartan cilexetil on all-cause mortality in the broad spectrum of symptomatic heart failure. The primary objective in each trial is to evaluate the effects on the combined endpoint of cardiovascular mortality or CHF hospitalization. Other endpoints include the effects on myocardial infarction, all-cause hospitalization, and resource utilization. CHARM is intended to randomize 6,500 patients with symptomatic heart failure from 26 countries in Europe, the United States, Canada, South Africa, and Australia. The CHARM program started to enroll patients in March 1999. The follow-up period is a minimum of 2 years. The study is expected to end in the third quarter of 2002.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
1071-9164
pubmed:author
pubmed:issnType
Print
pubmed:volume
5
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
276-82
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed-meshheading:10496201-Adolescent, pubmed-meshheading:10496201-Angiotensin Receptor Antagonists, pubmed-meshheading:10496201-Angiotensin-Converting Enzyme Inhibitors, pubmed-meshheading:10496201-Benzimidazoles, pubmed-meshheading:10496201-Biphenyl Compounds, pubmed-meshheading:10496201-Delayed-Action Preparations, pubmed-meshheading:10496201-Drug Evaluation, pubmed-meshheading:10496201-Heart Failure, pubmed-meshheading:10496201-Humans, pubmed-meshheading:10496201-Male, pubmed-meshheading:10496201-Myocardial Contraction, pubmed-meshheading:10496201-Prodrugs, pubmed-meshheading:10496201-Receptor, Angiotensin, Type 1, pubmed-meshheading:10496201-Receptor, Angiotensin, Type 2, pubmed-meshheading:10496201-Research Design, pubmed-meshheading:10496201-Safety, pubmed-meshheading:10496201-Stroke Volume, pubmed-meshheading:10496201-Survival Rate, pubmed-meshheading:10496201-Tetrazoles, pubmed-meshheading:10496201-Treatment Outcome, pubmed-meshheading:10496201-Ventricular Function, Left
pubmed:year
1999
pubmed:articleTitle
Candesartan in heart failure--assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators.
pubmed:affiliation
Department of Medicine, Sahlgrenska University Hospital, Göteborg, Sweden.
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study